Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
C

Cryo-Cell International Inc
AMEX:CCEL

Watchlist Manager
Cryo-Cell International Inc
AMEX:CCEL
Watchlist
Price: 3.4 USD 0.89% Market Closed
Market Cap: $27.4m
Write Note Create Alert Ask AI
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

Assets
+
3Y
-5%
5Y
+42%
10Y
+225%
Liabilities
+
3Y
+13%
5Y
+61%
10Y
+222%
Equity
+
3Y
-522%
5Y
-267%
10Y
-207%

Balance Sheet Decomposition
Cryo-Cell International Inc

Balance Sheet
Cryo-Cell International Inc

Rotate your device to view
Balance Sheet
Currency: USD
Nov-2001 Nov-2002 Nov-2003 Nov-2004 Nov-2005 Nov-2006 Nov-2007 Nov-2008 Nov-2009 Nov-2010 Nov-2011 Nov-2012 Nov-2013 Nov-2014 Nov-2015 Nov-2016 Nov-2017 Nov-2018 Nov-2019 Nov-2020 Nov-2021 Nov-2022 Nov-2023 Nov-2024
Assets
Cash & Cash Equivalents
6
2
2
5
8
7
3
4
7
8
6
3
4
3
4
3
6
6
7
10
8
2
0
1
Cash Equivalents
6
2
2
5
8
7
3
4
7
8
6
3
4
3
4
3
6
6
7
10
8
2
0
1
Short-Term Investments
0
3
1
1
0
1
1
1
1
1
1
0
0
0
1
1
0
1
1
0
0
0
1
3
Total Receivables
2
1
1
1
1
1
2
2
2
2
3
3
4
4
3
4
5
6
6
6
5
6
7
7
Accounts Receivables
2
1
1
1
1
1
2
2
2
2
3
3
3
4
3
4
5
6
6
6
5
6
7
7
Other Receivables
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
Inventory
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
Other Current Assets
0
0
0
1
1
1
1
1
1
1
4
3
2
1
2
0
1
1
1
1
1
1
1
1
Total Current Assets
8
6
4
7
10
11
8
7
11
13
14
9
9
8
10
9
13
15
15
19
16
10
9
13
PP&E Net
3
3
1
3
3
3
3
3
2
2
2
1
1
1
1
1
1
1
2
2
4
14
22
23
PP&E Gross
3
3
1
3
3
3
3
3
2
2
2
1
1
1
0
0
0
0
2
2
4
14
22
23
Accumulated Depreciation
1
1
1
1
1
2
3
3
4
4
5
5
6
0
0
0
0
0
7
7
8
8
8
6
Intangible Assets
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
1
1
1
2
1
1
1
Goodwill
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
2
2
2
2
2
2
2
Note Receivable
0
0
0
0
0
0
0
0
0
0
1
1
0
0
0
0
0
0
0
0
0
0
0
0
Long-Term Investments
6
3
1
1
1
1
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
Other Long-Term Assets
1
2
0
0
0
0
0
0
1
2
2
0
0
0
6
9
10
23
22
22
37
37
26
27
Other Assets
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
0
0
2
2
2
2
2
2
2
Total Assets
17
N/A
14
-20%
7
-48%
12
+61%
14
+22%
15
+3%
12
-20%
11
-6%
15
+33%
18
+24%
19
+7%
12
-37%
12
-7%
10
-11%
19
+91%
20
+0%
24
+22%
42
+77%
43
+1%
46
+8%
61
+31%
65
+7%
61
-6%
65
+6%
Liabilities
Accounts Payable
0
0
0
0
0
1
2
1
1
1
1
1
1
1
1
1
2
1
1
1
1
2
3
2
Accrued Liabilities
0
1
2
1
1
2
1
1
2
2
2
3
2
1
2
3
3
3
2
2
3
3
3
4
Short-Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Current Portion of Long-Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2
2
3
3
3
2
0
0
0
Other Current Liabilities
0
0
2
3
3
4
4
5
5
6
7
7
7
7
7
7
7
8
9
11
15
15
14
16
Total Current Liabilities
1
2
4
5
5
7
7
7
8
8
11
11
10
9
10
13
14
15
15
16
21
19
21
22
Long-Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
8
5
10
6
3
0
9
8
8
Deferred Income Tax
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Minority Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Other Liabilities
2
2
7
8
9
10
11
11
11
11
11
11
11
12
13
14
17
26
29
30
35
38
43
48
Total Liabilities
3
N/A
4
+49%
11
+157%
12
+13%
14
+11%
17
+21%
18
+9%
18
-2%
20
+10%
20
0%
22
+11%
21
-3%
21
-3%
21
+1%
24
+17%
35
+43%
36
+4%
51
+41%
50
-3%
49
-2%
56
+16%
66
+18%
72
+9%
78
+8%
Equity
Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Retained Earnings
8
13
27
23
22
25
30
31
29
26
27
34
34
34
25
27
24
25
22
19
17
22
31
33
Additional Paid In Capital
22
23
23
23
24
24
24
25
25
25
25
27
27
28
29
30
31
36
36
37
42
43
43
44
Treasury Stock
0
0
1
1
1
1
1
1
0
0
0
2
3
5
8
19
20
20
21
21
21
23
23
25
Other Equity
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total Equity
15
N/A
10
-34%
4
N/A
1
+78%
0
N/A
2
N/A
7
-215%
7
-6%
5
+26%
2
+70%
2
-59%
9
-266%
9
-3%
11
-16%
5
+54%
15
-211%
13
+19%
9
+29%
7
+22%
3
+62%
4
N/A
2
N/A
11
-624%
13
-20%
Total Liabilities & Equity
17
N/A
14
-20%
7
-48%
12
+61%
14
+22%
15
+3%
12
-20%
11
-6%
15
+33%
18
+24%
19
+7%
12
-37%
12
-7%
10
-11%
19
+91%
20
+0%
24
+22%
42
+77%
43
+1%
46
+8%
61
+31%
65
+7%
61
-6%
65
+6%
Shares Outstanding
Common Shares Outstanding
11
12
11
11
12
12
12
12
12
12
12
11
11
10
9
7
7
8
8
8
9
9
8
8

See Also

Summary
CCEL intrinsic value, competitors valuation, and company profile.
DCF Valuation
CCEL stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CCEL stock valuation using valuation multiples.
Wall Street Estimates
CCEL price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CCEL stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 317,100+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.